Literature DB >> 1658161

gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and Tennessee.

C E Fasching1, F C Tenover, T G Slama, L M Fisher, S Sreedharan, M Oram, K Willard, L M Sinn, D N Gerding, L R Peterson.   

Abstract

Mutational changes occurring at amino acid codons 84 and 85 located in the gyrA gene of methicillin-resistant Staphylococcus aureus (MRSA) were studied using radiolabeled oligonucleotide probes to examine the incidence of these ciprofloxacin resistance determinants in 30 MRSA isolates from Indiana, Minnesota, and Tennessee. Four separate oligonucleotide probes, one each corresponding to the wild-type sequence, a mutation at codon 84 (nucleotide 251), a mutation at codon 85 (nucleotide 253), and mutations at both, were used to examine the total genomic DNA from each of the 30 isolates, which had been restricted, electrophoresed, and Southern blotted. The probes indicated that 15 of the 28 ciprofloxacin-resistant isolates gave results consistent with a single mutation at codon 84. Four of the 28 ciprofloxacin-resistant strains had results consistent with a mutation at codon 84 and possibly at codon 85. The two ciprofloxacin-sensitive isolates from Tennessee showed homology with the wild-type probe sequence. Five isolates (4, Minnesota; 1, Tennessee) had no homology with any probe. By oligonucleotide probes, ciprofloxacin-resistant MRSA from diverse geographic regions contained similar gyrA mutations at codons 84 or 85 in 19 of 28 ciprofloxacin-resistant isolates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658161     DOI: 10.1093/infdis/164.5.976

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing.

Authors:  J J Goswitz; K E Willard; C E Fasching; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

3.  Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus.

Authors:  T Niga; H Yoshida; H Hattori; S Nakamura; H Ito
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Diagnosis of quinolone-resistant Coxiella burnetii strains by PCR-RFLP.

Authors:  I Spyridaki; A Psaroulaki; A Aransay; E Scoulica; Y Tselentis
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

5.  Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 6.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.

Authors:  T Takenouchi; F Tabata; Y Iwata; H Hanzawa; M Sugawara; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 9.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

10.  Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.

Authors:  H Fukuda; S Hori; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.